Group 1 - The core viewpoint of the article is that the price changes of the company's products are primarily influenced by supply and demand dynamics, with significant price increases for key products like Mancozeb and Chlorothalonil, while prices for products like Abamectin are expected to rebound after a seasonal decline [2][3] - The company indicated that the strong demand for its fungicides, such as Mancozeb and Chlorothalonil, is expected to lead to sustained price increases through 2025 [2] - The impact on the company's performance is influenced not only by price changes but also by factors such as volume and costs, with Mancozeb and Chlorothalonil expected to have a greater overall impact on performance compared to Abamectin [2]

Group 1 - The company, Limin Co., Ltd. (002734.SZ), reported that its current production and operational status is normal [2] - The pesticide industry is transitioning from off-peak to peak season, with demand gradually recovering [2] - The company anticipates that pesticide prices will stabilize and rebound in the near future [2]

利民股份（002734.SZ）11月26日在投资者互动平台表示，公司代森锰锌产能为45000吨/年，处于满产 满销状态；公司持有新河公司34%的股份，新河公司百菌清产能为30000吨/年，处于满产满销状态。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司拳头产品代森锰锌和百菌清，最新的产能是多 少？目前产能利用率怎么样？ ...

特别提示： 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 股票代码：002734 | 股票简称：利民股份 | 公告编号：2025-094 | | --- | --- | --- | | 债券代码：128144 | 债券简称：利民转债 | | 利民控股集团股份有限公司 关于利民转债预计触发赎回条件的提示性公告 自 2025 年 11 月 14 日至 2025 年 11 月 26 日，利民控股集团股份有限公司（以 下简称"公司"）股票已有 9 个交易日的收盘价不低于 "利民转债"当期转股价格 （即 8.10 元/股）的 130%（即 10.53 元/股），预计后续可能触发"利民转债"有 条件赎回条款。根据《公司公开发行可转换公司债券募集说明书》（以下简称《募 集说明书》）中有条件赎回条款的相关规定，届时公司董事会有权决定是否按照债 券面值加当期应计利息的价格赎回全部或部分未转股的"利民转债"。敬请广大投 资者详细了解可转换公司债券相关规定，并及时关注公司后续公告，注意投资风险。 一、可转换公司债券上市发行概况 （一）可转债发行情况 经中国证券监督管理委员会《 ...

Investment Rating - The report maintains a "Recommended" rating for the chemical industry [1] Core Views - The chemical industry is expected to benefit from the ongoing "anti-involution" measures, which may lead to a significant slowdown in global chemical capacity expansion. This shift is anticipated to enhance cash flow and dividend yields for companies in the sector, transforming them from cash-consuming entities to cash-generating ones [7][27] - The report highlights the potential for domestic substitutes for Japanese semiconductor materials due to rising tensions in Sino-Japanese relations, which could accelerate the domestic market's growth in this area [6] Summary by Sections Recent Trends - The chemical industry has shown a relative performance increase of 16.1% over the past 12 months, outperforming the CSI 300 index, which increased by 11.6% [4] Key Price Movements - DMC (Dimethyl Carbonate) prices rose to 4400 CNY/ton, up 14.29% week-on-week, driven by strong demand from the electrolyte sector [14] - Lithium battery electrolyte prices increased to 27000 CNY/ton, up 8.00% week-on-week, although profit margins for manufacturers are under pressure due to rising raw material costs [14] - Diammonium phosphate prices in East China reached 3850 CNY/ton, up 5.48% week-on-week, amid rising production costs [14] Investment Opportunities - The report identifies four key opportunities in the chemical sector: 1. Low-cost expansion, focusing on companies like Wanhua Chemical and Hualu Hengsheng [9] 2. Improved industry conditions, particularly in chromium salts and phosphate rock [10] 3. New materials with high growth potential, such as electronic chemicals and aerospace materials [11] 4. High dividend yields from state-owned enterprises in the chemical sector, including China Petroleum and China National Chemical [11] Company Tracking and Earnings Forecast - The report provides a detailed earnings forecast for key companies, indicating a positive outlook for several firms in the chemical sector, with many rated as "Buy" [28]

Group 1 - The core point of the news is that Limin Co., Ltd. experienced a decline in stock price and trading volume on November 20, with a drop of 3.89% and a transaction amount of 431 million yuan [1] - On November 20, Limin Co., Ltd. had a financing buy-in amount of 44.83 million yuan and a financing repayment of 64.24 million yuan, resulting in a net financing buy of -19.41 million yuan [1] - As of November 20, the total balance of margin trading for Limin Co., Ltd. was 470 million yuan, accounting for 5.95% of its circulating market value [1] Group 2 - As of November 10, the number of shareholders of Limin Co., Ltd. was 61,000, a decrease of 2.35% from the previous period, while the average circulating shares per person increased by 2.41% to 6,599 shares [2] - For the period from January to September 2025, Limin Co., Ltd. achieved an operating income of 3.599 billion yuan, representing a year-on-year growth of 7.62%, and a net profit attributable to the parent company of 390 million yuan, a significant increase of 661.66% [2] - Since its A-share listing, Limin Co., Ltd. has distributed a total of 919 million yuan in dividends, with 321 million yuan distributed in the last three years [2]

Core Points - Pingtan Development and Haixia Innovation have completed their suspension review and will resume trading on November 21, 2025 [1][2] - Eddy Precision and Hangcai Co. plan to repurchase shares [3] - Wenfeng Co.'s deputy general manager has been placed under investigation [4] - Kesi Co. has undergone a change in its actual controller [6][7] - Major events include the completion of restructuring investments by *ST Lian Shi and acquisitions by Jun Ting Hotel and Lek Electric [8][9] Group 1: Resumption of Trading - Pingtan Development's stock will resume trading on November 21, 2025, after confirming no significant changes in its operations or undisclosed major matters [1] - Haixia Innovation's stock will also resume trading on November 21, 2025, with similar confirmations regarding its operational status [2] Group 2: Share Repurchase Plans - Eddy Precision plans to repurchase shares with a total amount between 100 million and 200 million yuan, at a price not exceeding 27 yuan per share [3] - Hangcai Co. intends to repurchase shares using excess funds, with a total amount between 50 million and 100 million yuan, at a price not exceeding 80 yuan per share [3] Group 3: Investigations and Changes in Management - Wenfeng Co.'s deputy general manager, Qin Guofen, is under investigation, but the company states this will not significantly impact its operations [4] - Kesi Co. has changed its actual controller from Zhou Jiuqing and Zhou Xuming to Zhou Xuming alone following the death of Zhou Jiuqing [6][7] Group 4: Major Events - *ST Lian Shi has received a total of 1.238 billion yuan in restructuring investments from all investors [8] - Jun Ting Hotel has agreed to acquire the remaining 21% stake in Junlan Management for 79.8 million yuan, making it a wholly-owned subsidiary [9] - Lek Electric plans to transfer 90% of its subsidiary's equity to Chuangyuan Resources, with a target valuation of 235 million yuan [9]

证券日报网讯 11月20日晚间，利民股份发布公告称，全资子公司利民化学有限责任公司于近日收到江 苏省生态环境厅下发的《关于利民化学有限责任公司年产100吨新型高效多功能植保原药技改项目环境 影响报告书的批复》（苏环审【2025】90号）。 （文章来源：证券日报） ...

Group 1 - EVE Energy signed a procurement framework agreement with its affiliate, Smoore International, for continuous procurement of battery cells starting from January 1, 2026 [1] - Zhaoyi Information plans to issue H-shares and list on the Hong Kong Stock Exchange [1] - Fuke Environmental announced a change in its stock abbreviation to "Fuke Technology" effective November 26 [1] Group 2 - Dajia Weikang's shareholder and director terminated a share reduction plan ahead of schedule, having reduced 1% of total shares [2] - Aohong Electronics received approval from the China Securities Regulatory Commission for the issuance of convertible bonds [2] - Yingfeng Environment's controlling shareholder plans to issue exchangeable bonds not exceeding 1 billion yuan [2] Group 3 - Longshen Rongfa's subsidiary obtained a renewed drug production license covering various pharmaceutical products [4] - Xinhua News' subsidiary invested 15 million yuan in a fund with a total commitment of 221 million yuan [5] - Guang'an Aizhong appointed two new deputy general managers [6] Group 4 - Fosun Pharma's subsidiary's drug for gastric cancer treatment was included in the breakthrough therapy program by the National Medical Products Administration [7] - Nanjiao Foods reported a significant decline in October net profit due to rising raw material costs [8] - Nanfeng Co. won two nuclear power project bids totaling 928.7 million yuan [10] Group 5 - Puluo Pharmaceutical received a drug registration certificate for its Cefdinir capsules [11] - Liming Co.'s subsidiary received environmental approval for a new pesticide raw material project [12] - Longhua New Materials' expansion project for polyether polyols has commenced trial production [13] Group 6 - Pumen Technology's products received IVDR CE certification from TÜV Rheinland [15] - China Chemical reported new contracts worth 312.67 billion yuan from January to October [18] - China Nuclear Construction achieved new contracts totaling 123.84 billion yuan as of October [19] Group 7 - Changshu Bank's executives plan to purchase at least 550,000 shares of the bank [20] - Shandong Steel's subsidiary is applying for bankruptcy liquidation to focus on core business [21] - Huakang Clean is expected to win a bid for a purification system project worth 176 million yuan [23] Group 8 - Huawu Co. plans to internally transfer subsidiary equity [24] - Tianen Kang's subsidiary received clinical trial acceptance for a new drug [26] - Tianyi Medical's subsidiary obtained a medical device registration certificate for a blood dialysis product [27] Group 9 - Xuelang Environment is facing a pre-restructuring application from creditors [27] - Chitianhua's subsidiary resumed production after passing safety inspections [28] - Huaping Co.'s director plans to reduce 0.03% of company shares [30] Group 10 - Xizhuang Co. plans to establish a wholly-owned subsidiary in Singapore [31] - Ruisheng Intelligent's subsidiary won a 60.23 million yuan ICT project bid [32] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision [33] Group 11 - Fuguang Co.'s controlling shareholder plans to increase holdings between 80 million to 150 million yuan [34] - Ganyue Express reported a 13.68% increase in logistics revenue in October [39] - Jiangsu Sop terminated its 2025 private placement plan [41] Group 12 - Langke Intelligent's shareholders plan to reduce a total of 1.68% of company shares [42] - Yuantong Express reported an 8.97% increase in express product revenue in October [45] - Jinbei Automotive plans to invest 158 million yuan to acquire 52% of Zhongtuo Technology [46]

该批复同意利民化学在现有厂区内，建设新型高效多功能植保原药技改项目，项目建成后将形成年产 100吨氟吡菌酰胺原药产品生产能力。并且落实批复中提出的各项环保要求，确保污染物达标排放，严 格执行配套建设的环境保护设施与主体工程同时设计、同时施工、同时投产使用的环境保护"三同时"制 度。 利民股份(002734.SZ)公告，公司全资子公司利民化学有限责任公司(简称"利民化学")于近日收到江苏省 生态环境厅下发的《关于利民化学有限责任公司年产100吨新型高效多功能植保原药技改项目环境影响 报告书的批复》。 ...